The typical dose of a medication considered pivotal in Tuberculosis treatment effectively is much too low to account for modern-day physiques, UT Southwestern Medical Center researchers said.

Mycobacterium tuberculosis is arguably the world's most successful infectious agent because it knows how to avoid elimination by slowing its own growth to a crawl. Now, a report in the July 10 issue of the journal Cell, a Cell Press publication, offers new insight into the bugs' talent for meager living.

Current research suggests that Mycobacterium tuberculosis can evade the immune response. The related report by Rahman et al, "Compartmentalization of immune responses in human tuberculosis: few CD8+ effector T cells but elevated levels of FoxP3+ regulatory T cells in the granulomatous lesions," appears in the June 2009 issue of The American Journal of Pathology.

A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test, report scientists at The University of Texas Health Science Center at Houston in Nature Medicine's Advance Online Publication March 1. Their findings resulted from more than 6 years of research funded by the National Institutes of Health (NIH).

Older people suffer delayed tuberculosis treatment. A Taiwanese study of 78,118 pulmonary tuberculosis (PTB) cases, reported in the open access journal BMC Public Health has found that older people had both diagnosis and treatment delays in tuberculosis and those with an aboriginal background had a longer treatment delay.

An international team of biochemists has discovered how an experimental drug unleashes its destructive force inside the bacteria that cause tuberculosis (TB). The finding could help scientists develop ways to treat dormant TB infections, and suggests a strategy for drug development against other bacteria as well.

A link between the immune system and the self-cleaning system by which biological cells rid themselves of obsolete or toxic parts may one day yield new weapons in the fight against tuberculosis and other deadly infectious diseases. Scientists with the U.S. Department of Energy’s (DOE) Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered proteins residing in both systems that point to “cross-talk” between them.

New research has found that XDR-TB is increasingly common and more deadly than previously known. Extensively drug-resistant tuberculosis (XDR-TB) is a growing public health threat that is only just beginning to be understood by medical and public health officials.

Work could aid development of new treatments for such conditions as HIV, measles, and tuberculosis

About one third of the world's population has latent tuberculosis and roughly 9 million cases of active tuberculosis emerge annually resulting in 2-3million deaths. Most new cases occur in the most populated nations like India and China.

Patients receiving rifampicin-based anti-tuberculosis therapy are more likely to experience virological failure when starting nevirapine-based antiretroviral therapy, an HIV treatment that is widely used in developing countries because of lower cost, than when starting efavirenz-based antiretroviral therapy, according to a study in the August 6 issue of JAMA, a theme issue on HIV/AIDS.

The standard regimens to treat tuberculosis (TB) are inadequate in countries with high rates of multi-drug resistant (MDR) TB. In countries with high rates of MDR-TB, patients are nearly twice as likely to fail their initial treatment than those in countries with low rates, according to a new analysis of World Health Organization (WHO) data.